608 related articles for article (PubMed ID: 26810403)
1. Topical corticosteroid has no influence on inflammation or efficacy after ingenol mebutate treatment of grade I to III actinic keratoses (AK): A randomized clinical trial.
Erlendsson AM; Karmisholt KE; Haak CS; Stender IM; Haedersdal M
J Am Acad Dermatol; 2016 Apr; 74(4):709-15. PubMed ID: 26810403
[TBL] [Abstract][Full Text] [Related]
2. Efficacy and safety of ingenol mebutate gel in field treatment of actinic keratosis on full face, balding scalp, or approximately 250 cm
Hanke CW; Albrecht L; Skov T; Larsson T; Østerdal ML; Spelman L
J Am Acad Dermatol; 2020 Mar; 82(3):642-650. PubMed ID: 31374304
[TBL] [Abstract][Full Text] [Related]
3. Exploring the use of ingenol mebutate to prevent non-melanoma skin cancer.
Erlendsson AM
Dan Med J; 2017 Nov; 64(11):. PubMed ID: 29115209
[TBL] [Abstract][Full Text] [Related]
4. Daylight methyl-aminolevulinate photodynamic therapy versus ingenol mebutate for the treatment of actinic keratoses: an intraindividual comparative analysis.
Genovese G; Fai D; Fai C; Mavilia L; Mercuri SR
Dermatol Ther; 2016 May; 29(3):191-6. PubMed ID: 26799440
[TBL] [Abstract][Full Text] [Related]
5. Phase IV head-to-head randomized controlled trial comparing ingenol mebutate 0·015% gel with diclofenac sodium 3% gel for the treatment of actinic keratosis on the face or scalp.
Stockfleth E; Harwood CA; Serra-Guillén C; Larsson T; Østerdal ML; Skov T
Br J Dermatol; 2018 Feb; 178(2):433-442. PubMed ID: 29030864
[TBL] [Abstract][Full Text] [Related]
6. A randomized split-face clinical trial analyzing daylight photodynamic therapy with methyl aminolaevulinate vs ingenol mebutate gel for the treatment of multiple actinic keratoses of the face and the scalp.
Moggio E; Arisi M; Zane C; Calzavara-Pinton I; Calzavara-Pinton P
Photodiagnosis Photodyn Ther; 2016 Dec; 16():161-165. PubMed ID: 27530375
[TBL] [Abstract][Full Text] [Related]
7. Safety and Efficacy of Escalating Doses of Ingenol Mebutate for Field Treatment of Actinic Keratosis on the Full Face, Full Balding Scalp, or Chest.
Hanke CW; Berman B; Swanson N; Pariser DM; Weiss JS; Bukhalo M; Skov T; Villumsen J; Siegel D
J Drugs Dermatol; 2017 May; 16(5):438-444. PubMed ID: 28628679
[TBL] [Abstract][Full Text] [Related]
8. Ingenol mebutate gel for actinic keratosis.
Lebwohl M; Swanson N; Anderson LL; Melgaard A; Xu Z; Berman B
N Engl J Med; 2012 Mar; 366(11):1010-9. PubMed ID: 22417254
[TBL] [Abstract][Full Text] [Related]
9. A randomized trial comparing simultaneous vs. sequential field treatment of actinic keratosis with ingenol mebutate on two separate areas of the head and body.
Pellacani G; Peris K; Guillen C; Clonier F; Larsson T; Venkata R; Puig S
J Eur Acad Dermatol Venereol; 2015 Nov; 29(11):2192-8. PubMed ID: 26300464
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety of follow-up field treatment of actinic keratosis with ingenol mebutate 0·015% gel: a randomized, controlled 12-month study.
Garbe C; Basset-Seguin N; Poulin Y; Larsson T; Østerdal ML; Venkata R; Lear JT
Br J Dermatol; 2016 Mar; 174(3):505-13. PubMed ID: 26471889
[TBL] [Abstract][Full Text] [Related]
11. Tracking actinic keratosis of face and scalp treated with 0.015% ingenol mebutate to identify clinical and dermoscopic predictors of treatment response.
Pampena R; Benati E; Borsari S; Bombonato C; Lombardi M; Raucci M; Mirra M; Lallas A; Apalla Z; Papadimitriou I; Moscarella E; Kyrgidis A; Argenziano G; Pellacani G; Longo C
J Eur Acad Dermatol Venereol; 2018 Sep; 32(9):1461-1468. PubMed ID: 29356164
[TBL] [Abstract][Full Text] [Related]
12. Treatment of facial actinic keratoses with aminolevulinic acid photodynamic therapy (ALA-PDT) or ingenol mebutate 0.015% gel with and without prior treatment with ALA-PDT.
Berman B; Nestor MS; Newburger J; Park H; Swenson N
J Drugs Dermatol; 2014 Nov; 13(11):1353-6. PubMed ID: 25607702
[TBL] [Abstract][Full Text] [Related]
13. A multicentre, open, investigator-initiated phase IV clinical trial to evaluate the efficacy and safety of ingenol mebutate gel, 0·015% on the face and scalp, and 0·05% on the trunk and extremities, in Korean patients with actinic keratosis (PERFECT).
Kim YC; Yang JY; Yoon JS; Jo SJ; Ahn HH; Song KH; Lee DY; Chung KY; Won YH; Kim IH
Br J Dermatol; 2018 Oct; 179(4):836-843. PubMed ID: 29355904
[TBL] [Abstract][Full Text] [Related]
14. Evaluation of the tolerability and safety of a 0.015% ingenol mebutate gel compared to 5% 5-fluorouracil cream for the treatment of facial actinic keratosis: a prospective randomized trial.
Samorano LP; Torezan LA; Sanches JA
J Eur Acad Dermatol Venereol; 2015 Sep; 29(9):1822-7. PubMed ID: 25727104
[TBL] [Abstract][Full Text] [Related]
15. A seamless phase I/II dose-finding trial assessing ingenol disoxate (LEO 43204) for field treatment of actinic keratosis on the scalp.
Weiss J; Ulrich M; Bukhalo M; Østerdal ML; Bang B; Hanke CW
Br J Dermatol; 2017 Jun; 176(6):1456-1464. PubMed ID: 28078678
[TBL] [Abstract][Full Text] [Related]
16. Repeated Treatments with Ingenol Mebutate Prevents Progression of UV-Induced Photodamage in Hairless Mice.
Erlendsson AM; Thaysen-Petersen D; Bay C; Hald A; Skak K; Zibert JR; Paasch U; Wulf HC; Haedersdal M
PLoS One; 2016; 11(9):e0162597. PubMed ID: 27636884
[TBL] [Abstract][Full Text] [Related]
17. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis.
Anderson L; Schmieder GJ; Werschler WP; Tschen EH; Ling MR; Stough DB; Katsamas J
J Am Acad Dermatol; 2009 Jun; 60(6):934-43. PubMed ID: 19467365
[TBL] [Abstract][Full Text] [Related]
18. A Randomized Split-Face Clinical Trial of Photodynamic Therapy with Methyl Aminolevulinate versus Ingenol Mebutate Gel for the Treatment of Multiple Actinic Keratoses of the Face and Scalp.
Zane C; Fabiano A; Arisi M; Calzavara-Pinton P
Dermatology; 2016; 232(4):472-7. PubMed ID: 27578305
[TBL] [Abstract][Full Text] [Related]
19. Assessment of Efficacy and Irritation of Ingenol Mebutate Gel 0.015% Used With or Without Dimethicone Lotion for Treatment of Actinic Keratosis on the Face.
Jim On SC; Hashim PW; Nia JK; Lebwohl MG
J Drugs Dermatol; 2017 May; 16(5):432-436. PubMed ID: 28628678
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of Resource Utilization and Treatment Patterns in Patients with Actinic Keratosis in the United States.
Asche CV; Zografos P; Norlin JM; Urbanek B; Mamay C; Makin C; Erntoft S; Chen CC; Hines DM; Mark Siegel D
Value Health; 2016; 19(2):239-48. PubMed ID: 27021759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
